PCRX

Inducement Awards Granted: Pacira BioSciences announced the granting of inducement awards to 18 new employees, including stock options and restricted stock units, as part of their Amended and Restated 2014 Inducement Plan, approved by the Board's People & Compensation Committee without stockholder approval.

Company Overview: Pacira specializes in innovative, non-opioid pain therapies, offering products like EXPAREL, ZILRETTA, and ioveraº, and is developing a novel gene therapy, PCRX-201, aimed at treating prevalent diseases such as osteoarthritis.

Litigation Settlement: Pacira BioSciences has settled patent litigations with Fresenius Kabi, Jiangsu Hengrui Pharmaceuticals, and eVenus Pharmaceuticals regarding Exparel, allowing Fresenius to market a limited quantity of generic bupivacaine liposome injectable suspension starting in early 2030, with full entry permitted by 2039.

Financial Impact and Stock Performance: The settlement involves a payment of $7 million from Pacira to Fresenius, while the company's stock has seen a significant increase, rising 16.8% to $26.77 following positive analyst ratings and an increase in Exparel sales.

U.S. Stock Market Performance: U.S. stocks rose significantly, with the Dow Jones increasing over 1,300 points, driven by notable gains in various companies including Marvell Technology, which saw a 10.1% rise after Infineon Technologies announced a $2.5 billion acquisition of its Automotive Ethernet business.

Key Stock Movements: Several other companies experienced substantial stock increases, such as Agilon Health (31.8%), NextDecade Corporation (23.3%), and Pacira BioSciences (16.1%), reflecting positive market sentiment and strategic business developments.

U.S. Stock Market Update: U.S. stock futures are rising, with major indices like S&P 500 and Nasdaq 100 up around 1%, driven by positive comments from Treasury Secretary Bessent regarding tariff negotiations and optimistic forecasts from trade advisor Peter Navarro about avoiding a recession.

Earnings Report Highlights: Levi Strauss & Co. shares increased by 8% following strong earnings, while other notable movers include Spire Global up 35% after resolving litigation, and GameStop up 1.5% due to CEO purchases; however, The Greenbrier Companies saw a decline of 4.7% post-earnings.

Settlement Agreement: Pacira BioSciences has settled litigation with Fresenius Kabi and others regarding patents for EXPAREL, allowing Fresenius to sell limited amounts of generic bupivacaine liposome injectable suspension in the U.S. starting in 2030, with unlimited sales permitted from 2039.

Future Plans: Pacira remains confident in its patent portfolio and aims to advance its strategy in non-opioid pain therapies while addressing chronic pain needs in the U.S. market.

Litigation Settlement: Pacira BioSciences has settled its patent litigations with Fresenius Kabi, Jiangsu Hengrui Pharmaceuticals, and eVenus Pharmaceuticals regarding Exparel, allowing Fresenius to market a limited quantity of generic bupivacaine liposome injectable suspension starting in early 2030.

Patent Licensing Agreement: The settlement includes a licensing agreement that permits Fresenius to manufacture and sell an increasing volume of the generic product until reaching a maximum percentage by 2044, while also allowing for unlimited quantities beginning no earlier than 2039.

Pacira BioSciences Patent Settlement: Pacira BioSciences shares rose approximately 15% after announcing a settlement of a patent dispute with Fresenius Kabi and other drugmakers regarding its non-opioid pain therapy, Exparel.

Licensing Agreement Details: The agreement allows Fresenius to manufacture and sell limited amounts of generic Exparel starting in early 2030, with no volume limitations beginning in 2039, while affirming the strength of Pacira's intellectual property.

Analyst Rating: RBC Capital analyst Gregory Renza has maintained a Hold rating on Pacira Pharmaceuticals with a price target of $22.00, while the current share price is $23.10.

Market Consensus: The analyst consensus for Pacira Pharmaceuticals is also a Hold, with a higher price target consensus of $32.83, despite the company's one-year high being $31.67 and low at $11.16.

Gene Therapy Development: Pacira BioSciences has initiated the Phase 2 ASCEND study for PCRX-201, a novel gene therapy aimed at treating knee osteoarthritis by enhancing the production of the anti-inflammatory protein IL-1Ra, with initial results expected by late 2026.

Study Design and Objectives: The multicenter study will involve approximately 135 patients and assess the safety and efficacy of two different doses of PCRX-201 compared to saline, focusing on pain relief and functional improvement over a follow-up period of five years.

Pacira Biosciences Patent Settlement: Pacira Biosciences' stock rose following a positive patent settlement with Fresenius and others regarding its pain management drug Exparel, allowing limited sales of generic versions starting in 2030 while protecting its patents until 2044.

Biotech Sector Updates: The biotech sector faced challenges, with Sarepta Therapeutics pausing studies on its gene therapy Elevidys due to a patient death, while Amgen and Bristol Myers Squibb received FDA approvals for expanded uses of their drugs Uplizna and Opdivo, respectively.

Litigation Settlement: Pacira BioSciences has settled patent litigations with Fresenius Kabi, Jiangsu Hengrui Pharmaceuticals, and eVenus regarding EXPAREL, preventing Fresenius from marketing a generic version until after certain conditions are met.

Licensing Agreement: As part of the settlement, Pacira will license its patents to allow Fresenius to manufacture limited amounts of generic bupivacaine liposome injectable suspension starting in early 2030, with full unlimited production rights beginning no earlier than 2039.

Overview of the Article: The article discusses DOMA Perpetual's recent advancements and initiatives in the field of digital asset management, highlighting their innovative solutions and market impact.

Key Developments: It emphasizes the importance of blockchain technology in enhancing transparency and security for digital transactions, positioning DOMA Perpetual as a leader in this evolving industry.

Class Action Notice: Rosen Law Firm is reminding investors who purchased Pacira BioSciences securities between August 2, 2023, and August 8, 2024, of the March 14, 2025 deadline to join a class action lawsuit for potential compensation without upfront costs.

Allegations Against Pacira: The lawsuit claims that Pacira misled investors about the strength of its patent protections on Exparel, which affected its market position and led to financial damages when the truth was revealed.

Investor Alert: Faruqi & Faruqi, LLP is investigating potential claims against Pacira BioSciences, Inc. following a significant drop in stock price after the invalidation of its patent, encouraging affected investors to contact them for legal options.

Class Action Deadline: Investors who purchased Pacira securities between August 2, 2023, and August 8, 2024, are reminded of the March 14, 2025, deadline to seek lead plaintiff status in a federal securities class action against the company.

Class Action Notice: The Portnoy Law Firm is representing investors of Pacira BioSciences, Inc. in a class action lawsuit for those who purchased securities between August 2, 2023, and August 8, 2024, with a deadline to file a lead plaintiff motion by March 14, 2025.

Stock Price Decline: Following a court ruling that invalidated a key patent related to its main product Exparel, Pacira's stock price dropped significantly from $22.36 to $11.70 per share in one day, raising concerns about increased competition and litigation costs.

Class Action Notice: The Gross Law Firm is notifying shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) about a class action lawsuit due to significant stock price decline following the invalidation of a key patent related to their main product, Exparel.

Important Deadlines: Shareholders who purchased shares between August 2, 2023, and August 8, 2024, are encouraged to register for potential lead plaintiff status by March 14, 2025, with no cost or obligation to participate in the case.

Class Action Lawsuit: Levi & Korsinsky, LLP has initiated a class action lawsuit on behalf of investors in Pacira BioSciences, Inc. due to alleged securities fraud that occurred between August 2, 2023, and August 8, 2024, following the invalidation of a key patent affecting the company's revenue.

Impact on Stock Price: Following the announcement of the patent's invalidity, Pacira's stock price plummeted over 47% in one day, highlighting significant financial losses for investors during this period.

Class Action Lawsuit Notification: Levi & Korsinsky, LLP has announced a class action securities lawsuit for investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) due to alleged securities fraud that occurred between August 2, 2023, and August 8, 2024.

Impact of Patent Invalidation: The lawsuit follows a significant drop in Pacira's stock price after the company disclosed that its key patent for Exparel was deemed invalid, raising concerns about future revenue and potential market competition.

Class Action Lawsuit Against Pacira BioSciences: Investors have until March 14, 2025, to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences for failing to disclose material information during the Class Period, which led to a significant drop in share price after a patent ruling.

Legal Representation and Contact Information: Kahn Swick & Foti, LLC offers assistance to affected investors seeking to understand their legal rights and potentially serve as lead plaintiffs in the case, with contact details provided for inquiries.

Class Action Lawsuit Filed: A class action lawsuit has been initiated against Pacira Biosciences, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to contact Pomerantz LLP for participation by March 14, 2025.

Patent Infringement Impact: The lawsuit follows a significant drop in Pacira's stock price after a court invalidated its patent for the Exparel pain treatment, resulting in a 47.67% decrease in share value on August 9, 2024.